Global /Israel /Healthcare /Biotechnology /CMMB

Chemomab Therapeutics Ltd.

CMMB

• NASDAQ: CMMB • Delayed

1.46USD -1%

As of 5 June 2026, Chemomab Therapeutics Ltd. has a market cap of $10.51M USD, ranking #41041 globally and #542 in Israel. It ranks #3649 in the Healthcare sector, and #714 in the Biotechnology industry.

Global Rank

41041

Country Rank

542

Sector Rank

3649

Industry Rank

714

Key Stats

Market Cap

$10.51MUSD

Enterprise Value

$290.57KUSD

EBITDA (TTM)

-$9.5MUSD

Net Income (TTM)

-$9.0MUSD

PB Ratio

0.9

Company Profile

Country (HQ)

Israel

Sector

Healthcare

Industry

Biotechnology

CEO

Adi George open_in_new

Employees

Founded

2004

Website

chemomab.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1%	-7.2%	5.5%	-4.9%	-51%	-6.7%	-71%	-74%	-99%

News

CMMB Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CMMB Chemomab Therapeutics Ltd ADR ISIN: US16385C2035 Shares Out.: Shares Outstanding: 7.2M¹ Shares Float: 6.874M² TV: TradingView: NASDAQ: CMMB SA: Stock Analysis: NASDAQ: CMMB YF: Yahoo Finance: CMMB GF: Google Finance: NASDAQ: CMMB NQ: NASDAQ: CMMB BA: Barron's: CMMB MS: Morningstar: XNAS: CMMB	1.46 USD	TV: TradingView: NASDAQ: CMMB SA: Stock Analysis: NASDAQ: CMMB YF: Yahoo Finance: CMMB GF: Google Finance: NASDAQ: CMMB NQ: NASDAQ: CMMB BA: Barron's: CMMB MS: Morningstar: XNAS: CMMB

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Similar Companies

Industry: Biotechnology (Israel)

Name	Market Cap (USD) diff.	PE	Country
Kamada Ltd. NASDAQ: KMDA	$470.55M 4K%	23.3	Israel
Israel Canada Hotels Ltd. TLV: DNA	$335.01M 962.09M ILS 3K%	267.3	Israel
Compugen Ltd. NASDAQ: CGEN	$245.84M 2K%	6.9	Israel
Enlivex Ltd. NASDAQ: ENLV	$190.26M 2K%	0.0	Israel
Kadimastem Ltd. TLV: KDST	$56.08M 161.06M ILS 433%	-	Israel
Pluri Inc. NASDAQ: PLUR	$34.07M 224%	-	Israel

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 2M%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 2M%	19.0	United States
argenx SE EBR: ARGX	$48.01B 41.39B EUR 457K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.36B 68.19T KRW 422K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.98B 60.27B AUD 409K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.55B 33.71B CHF 405K%	37.2	Switzerland

chevron_leftBack